GRK3 deficiency elicits brain immune activation and psychosis.

Animals Bipolar Disorder / genetics Brain / metabolism Kynurenic Acid / metabolism Mice Psychotic Disorders / genetics Schizophrenia / metabolism

Journal

Molecular psychiatry

ISSN: 1476-5578

Titre abrégé: Mol Psychiatry

Pays: England

ID NLM: 9607835

Informations de publication

Date de publication:
11 2021

Historique:

received: 18 07 2020

accepted: 07 04 2021

pubmed: 13 5 2021

medline: 15 3 2022

entrez: 12 5 2021

Statut: ppublish

Résumé

The G protein-coupled receptor kinase (GRK) family member protein GRK3 has been linked to the pathophysiology of schizophrenia and bipolar disorder. Expression, as well as protein levels, of GRK3 are reduced in post-mortem prefrontal cortex of schizophrenia subjects. Here, we investigate functional behavior and neurotransmission related to immune activation and psychosis using mice lacking functional Grk3 and utilizing a variety of methods, including behavioral, biochemical, electrophysiological, molecular, and imaging methods. Compared to wildtype controls, the Grk3

Identifiants

DOI: 10.1038/s41380-021-01106-0 PMID: 33976392 PMC: PMC8760053

pubmed: 33976392

doi: 10.1038/s41380-021-01106-0

pii: 10.1038/s41380-021-01106-0

pmc: PMC8760053

doi:

Substances chimiques

Kynurenic Acid H030S2S85J

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

6820-6832

Subventions

Organisme : NIMH NIH HHS

ID : R01 MH091407

Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Références

Gurevich EV, Tesmer JJ, Mushegian A, Gurevich VV. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharm Ther. 2012;133:40–69.

doi: 10.1016/j.pharmthera.2011.08.001

Steury MD, Lucas PC, McCabe LR, Parameswaran N. G-protein-coupled receptor kinase-2 is a critical regulator of TNFalpha signaling in colon epithelial cells. Biochem J. 2017;474:2301–2313.

pubmed: 28572156 doi: 10.1042/BCJ20170093

Tesmer VM, Kawano T, Shankaranarayanan A, Kozasa T, Tesmer JJ. Snapshot of activated G proteins at the membrane: the Galphaq-GRK2-Gbetagamma complex. Science. 2005;310:1686–1690.

pubmed: 16339447 doi: 10.1126/science.1118890

Arriza JL, Dawson TM, Simerly RB, Martin LJ, Caron MG, Snyder SH, et al. The G-protein-coupled receptor kinases beta ARK1 and beta ARK2 are widely distributed at synapses in rat brain. J Neurosci. 1992;12:4045–4055.

pubmed: 1403099 pmcid: 6575981 doi: 10.1523/JNEUROSCI.12-10-04045.1992

Erdtmann-Vourliotis M, Mayer P, Ammon S, Riechert U, Hollt V. Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res Mol Brain Res. 2001;95:129–137.

pubmed: 11687284 doi: 10.1016/S0006-8993(01)03046-3

Guindalini C, Collier D, Laranjeira R, Barrett TB, Kelsoe J, Castelo A, et al. Association analysis of GRK3 gene promoter variants in cocaine abuse. Psychiatr Genet. 2007;17:239–242.

pubmed: 17621168 doi: 10.1097/YPG.0b013e3280ae6c3d

Dinieri JA, Nemeth CL, Parsegian A, Carle T, Gurevich VV, Gurevich E, et al. Altered sensitivity to rewarding and aversive drugs in mice with inducible disruption of cAMP response element-binding protein function within the nucleus accumbens. J Neurosci. 2009;29:1855–1859.

pubmed: 19211892 pmcid: 2666984 doi: 10.1523/JNEUROSCI.5104-08.2009

Gluck L, Loktev A, Mouledous L, Mollereau C, Law PY, Schulz S. Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry. 2014;76:767–774.

pubmed: 24629717 pmcid: 4119866 doi: 10.1016/j.biopsych.2014.01.021

Loh R, Chau L, Aijaz A, Wu K, Galvez R. Antagonizing the different stages of kappa opioid receptor activation selectively and independently attenuates acquisition and consolidation of associative memories. Behav Brain Res. 2017;323:1–10.

pubmed: 28119127 doi: 10.1016/j.bbr.2017.01.032

Soderlund J, Schroder J, Nordin C, Samuelsson M, Walther-Jallow L, Karlsson H, et al. Activation of brain interleukin-1beta in schizophrenia. Mol Psychiatry. 2009;14:1069–1071.

pubmed: 19920835 pmcid: 2848473 doi: 10.1038/mp.2009.52

Soderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S, et al. Elevation of cerebrospinal fluid interleukin-1ss in bipolar disorder. J Psychiatry Neurosci. 2011;36:114–118.

pubmed: 21138659 pmcid: 3044194 doi: 10.1503/jpn.100080

Fillman SG, Cloonan N, Catts VS, Miller LC, Wong J, McCrossin T, et al. Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia. Mol Psychiatry. 2013;18:206–214.

pubmed: 22869038 doi: 10.1038/mp.2012.110

Woo JJ, Pouget JG, Zai CC, Kennedy JL. The complement system in schizophrenia: where are we now and what’s next? Mol Psychiatry. 2020;25:114–130.

pubmed: 31439935 doi: 10.1038/s41380-019-0479-0

Pape K, Tamouza R, Leboyer M, Zipp F. Immunoneuropsychiatry—novel perspectives on brain disorders. Nat Rev Neurol. 2019;15:317–328.

pubmed: 30988501 doi: 10.1038/s41582-019-0174-4

Brown AS, Meyer U. Maternal Immune Activation and Neuropsychiatric Illness: A Translational Research Perspective. Am J Psychiatry. 2018;175:1073–1083.

pubmed: 30220221 pmcid: 6408273 doi: 10.1176/appi.ajp.2018.17121311

Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47:401–406.

pubmed: 23290488 doi: 10.1016/j.jpsychires.2012.12.001

Schwieler L, Larsson MK, Skogh E, Kegel ME, Orhan F, Abdelmoaty S, et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia—significance for activation of the kynurenine pathway. J Psychiatry Neurosci. 2015;40:126–133.

pubmed: 25455350 pmcid: 4354818 doi: 10.1503/jpn.140126

Sellgren CM, Kegel ME, Bergen SE, Ekman CJ, Olsson S, Larsson M, et al. A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. Mol Psychiatry. 2016;21:1342–1350.

pubmed: 26666201 doi: 10.1038/mp.2015.186

Trépanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Mol Psychiatry. 2016;21:1009–1026.

pubmed: 27271499 pmcid: 4960446 doi: 10.1038/mp.2016.90

Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45:984–994.

pubmed: 23933821 doi: 10.1038/ng.2711

Hill SK, Reilly JL, Keefe RS, Gold JM, Bishop JR, Gershon ES, et al. Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. Am J Psychiatry. 2013;170:1275–1284.

pubmed: 23771174 pmcid: 5314430 doi: 10.1176/appi.ajp.2013.12101298

Tarrant TK, Billard MJ, Timoshchenko RG, McGinnis MW, Serafin DS, Foreman O, et al. G protein-coupled receptor kinase-3-deficient mice exhibit WHIM syndrome features and attenuated inflammatory responses. J Leukoc Biol. 2013;94:1243–1251.

pubmed: 23935208 pmcid: 3828605 doi: 10.1189/jlb.0213097

Balabanian K, Levoye A, Klemm L, Lagane B, Hermine O, Harriague J, et al. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest. 2008;118:1074–1084.

pubmed: 18274673 pmcid: 2242619

Steury MD, McCabe LR, Parameswaran NG. Protein-Coupled Receptor Kinases in the Inflammatory Response and Signaling. Adv Immunol. 2017;136:227–277.

pubmed: 28950947 pmcid: 5730335 doi: 10.1016/bs.ai.2017.05.003

Bychkov ER, Ahmed MR, Gurevich VV, Benovic JL, Gurevich EV. Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder. Neurobiol Dis. 2011;44:248–258.

pubmed: 21784156 pmcid: 3166984 doi: 10.1016/j.nbd.2011.07.009

Barrett TB, Hauger RL, Kennedy JL, Sadovnick AD, Remick RA, Keck PE, et al. Evidence that a single nucleotide polymorphism in the promoter of the G protein receptor kinase 3 gene is associated with bipolar disorder. Mol Psychiatry. 2003;8:546–557.

pubmed: 12808434 doi: 10.1038/sj.mp.4001268

McCarthy MJ, Barrett TB, Nissen S, Kelsoe JR, Turner EE. Allele specific analysis of the ADRBK2 gene in lymphoblastoid cells from bipolar disorder patients. J Psychiatr Res. 2010;44:201–208.

pubmed: 19766236 doi: 10.1016/j.jpsychires.2009.08.010

Zhou X, Barrett TB, Kelsoe JR. Promoter variant in the GRK3 gene associated with bipolar disorder alters gene expression. Biol Psychiatry. 2008;64:104–110.

pubmed: 18359007 pmcid: 6528791 doi: 10.1016/j.biopsych.2007.12.017

Liu XC, Holtze M, Powell SB, Terrando N, Larsson MK, Persson A, et al. Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment—role of brain kynurenic acid. Brain Behav Immun. 2014;36:80–89.

pubmed: 24140727 doi: 10.1016/j.bbi.2013.10.010

Olsson SK, Andersson AS, Linderholm KR, Holtze M, Nilsson-Todd LK, Schwieler L, et al. Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol. 2009;12:501–512.

pubmed: 18796185 doi: 10.1017/S1461145708009383

Larsson MK, Faka A, Bhat M, Imbeault S, Goiny M, Orhan F, et al. Repeated LPS injection induces distinct changes in the Kynurenine pathway in mice. Neurochem Res. 2016;41:2243–2255.

pubmed: 27165635 doi: 10.1007/s11064-016-1939-4

Vinkers CH, Risbrough VB, Geyer MA, Caldwell S, Low MJ, Hauger RL. Role of dopamine D1 and D2 receptors in CRF-induced disruption of sensorimotor gating. Pharm Biochem Behav. 2007;86:550–558.

doi: 10.1016/j.pbb.2007.01.018

Tufvesson-Alm M, Schwieler L, Schwarcz R, Goiny M, Erhardt S, Engberg G. Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia. Neuropharmacology. 2018;138:130–139.

pubmed: 29879409 pmcid: 6794148 doi: 10.1016/j.neuropharm.2018.06.003

van der Walt S, Schonberger JL, Nunez-Iglesias J, Boulogne F, Warner JD, Yager N, et al. scikit-image: image processing in Python. PeerJ. 2014;2:e453.

pubmed: 25024921 pmcid: 4081273 doi: 10.7717/peerj.453

Ayers-Ringler JR, Oliveros A, Qiu Y, Lindberg DM, Hinton DJ, Moore RM, et al. Label-free proteomic analysis of protein changes in the striatum during chronic ethanol use and early withdrawal. Front Behav Neurosci. 2016;10:46.

pubmed: 27014007 pmcid: 4786553 doi: 10.3389/fnbeh.2016.00046

Oliveros A, Starski P, Lindberg D, Choi S, Heppelmann CJ, Dasari S, et al. Label-free neuroproteomics of the hippocampal-accumbal circuit reveals deficits in neurotransmitter and neuropeptide signaling in mice lacking ethanol-sensitive adenosine transporter. J Proteome Res. 2017;16:1445–1459.

pubmed: 27998058 pmcid: 5384880 doi: 10.1021/acs.jproteome.6b00830

Bergen SE, O’Dushlaine CT, Ripke S, Lee PH, Ruderfer DM, Akterin S, et al. Genome-wide association study in a Swedish population yields support for greater CNV and MHC involvement in schizophrenia compared with bipolar disorder. Mol Psychiatry. 2012;17:880–886.

pubmed: 22688191 pmcid: 3724337 doi: 10.1038/mp.2012.73

Olsson SK, Sellgren C, Engberg G, Landen M, Erhardt S. Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord. 2012;14:719–726.

pubmed: 23030601 doi: 10.1111/bdi.12009

Wall PM, Messier C. Infralimbic kappa opioid and muscarinic M1 receptor interactions in the concurrent modulation of anxiety and memory. Psychopharmacol. 2002;160:233–244.

doi: 10.1007/s00213-001-0979-9

Powell SB, Weber M, Geyer MA. Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders. Curr Top Behav Neurosci. 2012;12:251–318.

pubmed: 22367921 pmcid: 3357439 doi: 10.1007/7854_2011_195

Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron. 2006;52:179–196.

pubmed: 17015235 doi: 10.1016/j.neuron.2006.09.023

van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull. 2010;36:246–270.

pubmed: 19900963 doi: 10.1093/schbul/sbp132

Gainetdinov RR, Bohn LM, Sotnikova TD, Cyr M, Laakso A, Macrae AD, et al. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron. 2003;38:291–303.

pubmed: 12718862 doi: 10.1016/S0896-6273(03)00192-2

Gurevich EV, Gainetdinov RR, Gurevich VV. G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharm Res. 2016;111:1–16.

doi: 10.1016/j.phrs.2016.05.010

Ridet JL, Malhotra SK, Privat A, Gage FH. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 1997;20:570–577.

pubmed: 9416670 doi: 10.1016/S0166-2236(97)01139-9

Paco S, Pozas E, Aguado F. Secretogranin III is an astrocyte granin that is overexpressed in reactive glia. Cereb Cortex. 2010;20:1386–1397.

pubmed: 19892786 doi: 10.1093/cercor/bhp202

Sellgren CM, Gracias J, Watmuff B, Biag JD, Thanos JM, Whittredge PB, et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat Neurosci. 2019;22:374–385.

pubmed: 30718903 pmcid: 6410571 doi: 10.1038/s41593-018-0334-7

Erhardt S, Schwieler L, Imbeault S, Engberg G. The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology. 2017;112:297–306.

pubmed: 27245499 doi: 10.1016/j.neuropharm.2016.05.020

Miller CL, Llenos IC, Dulay JR, Barillo MM, Yolken RH, Weis S. Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis. 2004;15:618–629.

pubmed: 15056470 doi: 10.1016/j.nbd.2003.12.015

Erhardt S, Schwieler L, Emanuelsson C, Geyer M. Endogenous kynurenic acid disrupts prepulse inhibition. Biol Psychiatry. 2004;56:255–260.

pubmed: 15312813 doi: 10.1016/j.biopsych.2004.06.006

Singh N, Scalise M, Galluccio M, Wieder M, Seidel T, Langer T et al. Discovery of potent inhibitors for the large neutral amino acid transporter 1 (LAT1) by structure-based methods. Int J Mol Sci. 2018;20:27.

Carlsson A, Holmin T, Lindqvist M, Siesjö BK. Effect of hypercapnia and hypocapnia on tryptophan and tyrosine hydroxylation in rat brain. Acta Physiol Scand. 1977;99:503–509.

pubmed: 16438 doi: 10.1111/j.1748-1716.1977.tb10404.x

Feng YH, Wang L, Wang Q, Li X, Zeng R, Gorodeski GI. ATP stimulates GRK-3 phosphorylation and beta-arrestin-2-dependent internalization of P2X7 receptor. Am J Physiol Cell Physiol. 2005;288:C1342–1356.

pubmed: 15728711 doi: 10.1152/ajpcell.00315.2004

Giuliani AL, Sarti AC, Falzoni S, Di Virgilio F. The P2X7 receptor-interleukin-1 liaison. Front Pharm. 2017;8:123.

doi: 10.3389/fphar.2017.00123

Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465–477.

pubmed: 22678511 pmcid: 3681811 doi: 10.1038/nrn3257

Savio LEB, de Andrade Mello P, da Silva CG, Coutinho-Silva R. The P2X7 receptor in inflammatory diseases: angel or demon? Front Pharm. 2018;9:52.

doi: 10.3389/fphar.2018.00052

Pannell M, Economopoulos V, Wilson TC, Kersemans V, Isenegger PG, Larkin JR, et al. Imaging of translocator protein upregulation is selective for pro-inflammatory polarized astrocytes and microglia. Glia. 2020;68:280–297.

pubmed: 31479168 doi: 10.1002/glia.23716

Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–487.

pubmed: 28099414 pmcid: 5404890 doi: 10.1038/nature21029

Srinivasan R, Lu TY, Chai H, Xu J, Huang BS, Golshani P, et al. New Transgenic Mouse Lines for Selectively Targeting Astrocytes and Studying Calcium Signals in Astrocyte Processes In Situ and In Vivo. Neuron. 2016;92:1181–1195.

pubmed: 27939582 pmcid: 5403514 doi: 10.1016/j.neuron.2016.11.030

Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity. 2019; 50: 253–271 e256.

Jimenez-Mateos EM, Arribas-Blazquez M, Sanz-Rodriguez A, Concannon C, Olivos-Ore LA, Reschke CR, et al. microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus. Sci Rep. 2015;5:17486.

pubmed: 26631939 pmcid: 4668358 doi: 10.1038/srep17486

Rodrigues RJ, Tome AR, Cunha RA. ATP as a multi-target danger signal in the brain. Front Neurosci. 2015;9:148.

pubmed: 25972780 pmcid: 4412015 doi: 10.3389/fnins.2015.00148

Erhardt S, Pocivavsek A, Repici M, Liu XC, Imbeault S, Maddison DC, et al. Adaptive and behavioral changes in kynurenine 3-monooxygenase knockout mice: relevance to psychotic disorders. Biol Psychiatry. 2017;82:756–765.

pubmed: 28187857 doi: 10.1016/j.biopsych.2016.12.011

Chess AC, Bucci DJ. Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding. Behav Brain Res. 2006;170:326–332.

pubmed: 16621049 doi: 10.1016/j.bbr.2006.03.006

Shepard PD, Joy B, Clerkin L, Schwarcz R. Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology. 2003;28:1454–1462.

pubmed: 12700696 doi: 10.1038/sj.npp.1300188

Geyer MA. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res. 2008;14:71–78.

pubmed: 18790726 pmcid: 2667110 doi: 10.1007/BF03033576

Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012;16:27–34.

pubmed: 22169777 doi: 10.1016/j.tics.2011.11.015

Kesby JP, Eyles DW, McGrath JJ, Scott JG. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl Psychiatry. 2018;8:30.

pubmed: 29382821 pmcid: 5802623 doi: 10.1038/s41398-017-0071-9

Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999;46:56–72.

pubmed: 10394474 doi: 10.1016/S0006-3223(99)00067-0

Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93:9235–9240.

pubmed: 8799184 pmcid: 38625 doi: 10.1073/pnas.93.17.9235

Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA. 1997;94:2569–2574.

pubmed: 9122236 pmcid: 20129 doi: 10.1073/pnas.94.6.2569

Erhardt S, Blennow K, Nordin C, Skogh E, Lindstrom LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001;313:96–98.

pubmed: 11684348 doi: 10.1016/S0304-3940(01)02242-X

Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav. 2007;92:203–209.

pubmed: 17573079 doi: 10.1016/j.physbeh.2007.05.025

Linderholm K, Powell S, Olsson E, Holtze M, Snodgrass R, Erhardt S. Role of the NMDA-receptor in Prepulse Inhibition in the Rat. Int J Tryptophan Res. 2010;3:1–12.

pubmed: 22084584 pmcid: 3195246 doi: 10.4137/IJTR.S4260

Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001;50:521–530.

pubmed: 11600105 doi: 10.1016/S0006-3223(01)01078-2